189 related articles for article (PubMed ID: 20137766)
1. Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188.
Fisher A; Watling M; Smith A; Knight A
Int J Clin Pharmacol Ther; 2010 Feb; 48(2):138-45. PubMed ID: 20137766
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 - 800 µg in healthy volunteers.
Fisher A; Watling M; Smith A; Knight A
Int J Clin Pharmacol Ther; 2010 Dec; 48(12):860-7. PubMed ID: 21084042
[TBL] [Abstract][Full Text] [Related]
3. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
[TBL] [Abstract][Full Text] [Related]
4. Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study.
Parikh N; Goskonda V; Chavan A; Dillaha L
Clin Ther; 2013 Mar; 35(3):236-43. PubMed ID: 23497761
[TBL] [Abstract][Full Text] [Related]
5. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study.
Vasisht N; Gever LN; Tagarro I; Finn AL
Clin Drug Investig; 2009; 29(10):647-54. PubMed ID: 19715381
[TBL] [Abstract][Full Text] [Related]
6. Faster absorption and higher systemic bioavailability of intranasal fentanyl spray compared to oral transmucosal fentanyl citrate in healthy subjects.
Nave R; Schmitt H; Popper L
Drug Deliv; 2013; 20(5):216-23. PubMed ID: 23650968
[TBL] [Abstract][Full Text] [Related]
7. Effect of dosing interval on pharmacokinetics of fentanyl pectin nasal spray from a crossover study.
Chen C; Bujanover S; Gupta A
J Opioid Manag; 2015; 11(2):139-46. PubMed ID: 25901479
[TBL] [Abstract][Full Text] [Related]
8. A pharmacokinetic assessment of an alternate titration strategy for fentanyl pectin nasal spray.
Perelman M; Knight A
Int J Clin Pharmacol Ther; 2013 Dec; 51(12):942-7. PubMed ID: 24120713
[TBL] [Abstract][Full Text] [Related]
9. Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl.
Perelman M; Fisher AN; Smith A; Knight A
Int J Clin Pharmacol Ther; 2013 May; 51(5):349-56. PubMed ID: 23458227
[TBL] [Abstract][Full Text] [Related]
10. Dose proportionality of fentanyl buccal tablet in doses ranging from 600 to 1300 microg in healthy adult subjects: a randomized, open-label, four-period, crossover, single-centre study.
Darwish M; Kirby M; Robertson P; Tracewell W; Xie F
Clin Drug Investig; 2010; 30(6):365-73. PubMed ID: 20441245
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers.
Darwish M; Kirby M; Robertson P; Tracewell W; Jiang JG
Clin Ther; 2006 May; 28(5):707-14. PubMed ID: 16861092
[TBL] [Abstract][Full Text] [Related]
12. Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain.
Radbruch L; Torres LM; Ellershaw JE; Gatti A; Luis Lerzo G; Revnic J; Taylor D
Support Care Cancer; 2012 Mar; 20(3):565-73. PubMed ID: 21424794
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and dose proportionality of fentanyl sublingual spray: a single-dose 5-way crossover study.
Parikh N; Goskonda V; Chavan A; Dillaha L
Clin Drug Investig; 2013 Jun; 33(6):391-400. PubMed ID: 23605506
[TBL] [Abstract][Full Text] [Related]
14. A report on the long-term use of fentanyl pectin nasal spray in patients with recurrent breakthrough pain.
Taylor D; Radbruch L; Revnic J; Torres LM; Ellershaw JE; Perelman M
J Pain Symptom Manage; 2014 Jun; 47(6):1001-7. PubMed ID: 24128821
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain.
Portenoy RK; Burton AW; Gabrail N; Taylor D;
Pain; 2010 Dec; 151(3):617-624. PubMed ID: 20800358
[TBL] [Abstract][Full Text] [Related]
16. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate.
Darwish M; Kirby M; Robertson P; Tracewell W; Jiang JG
J Clin Pharmacol; 2007 Mar; 47(3):343-50. PubMed ID: 17322146
[TBL] [Abstract][Full Text] [Related]
17. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).
Coluzzi PH; Schwartzberg L; Conroy JD; Charapata S; Gay M; Busch MA; Chavez J; Ashley J; Lebo D; McCracken M; Portenoy RK
Pain; 2001 Mar; 91(1-2):123-30. PubMed ID: 11240084
[TBL] [Abstract][Full Text] [Related]
18. A pharmacokinetic study to compare two simultaneous 400 microg doses with a single 800 microg dose of oral transmucosal fentanyl citrate.
Lee M; Kern SE; Kisicki JC; Egan TD
J Pain Symptom Manage; 2003 Aug; 26(2):743-7. PubMed ID: 12906959
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients.
Portenoy RK; Raffaeli W; Torres LM; Sitte T; Deka AC; Herrera IG; Wallace MS;
J Opioid Manag; 2010; 6(5):319-28. PubMed ID: 21046929
[TBL] [Abstract][Full Text] [Related]
20. Multiple dose pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers.
Egan TD; Sharma A; Ashburn MA; Kievit J; Pace NL; Streisand JB
Anesthesiology; 2000 Mar; 92(3):665-73. PubMed ID: 10719944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
